tdrbouz-1
tdrbouz / iStockphoto.com
29 May 2018Big Pharma

European Commission proposes SPC waiver to boost generics

The European Commission has proposed a change in IP rules to allow pharmaceutical companies to produce generic drugs for export to non-EU countries that don’t have patent protection.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
9 August 2018   A proposed change to supplementary protection certificate rules in the EU could lead to the development of less innovative medicines, according to the Irish Pharmaceutical Healthcare Association.
Big Pharma
18 October 2018   The supplementary protection certificate manufacturing waiver “sends a worrying global signal that the EU is weakening its IP framework”, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Big Pharma
16 November 2018   Supplementary protection certificates are hugely important to MSD’s business, according to Elena Böhles, assistant counsel at the pharmaceutical company, based in Hertfordshire, UK.

More on this story

Big Pharma
9 August 2018   A proposed change to supplementary protection certificate rules in the EU could lead to the development of less innovative medicines, according to the Irish Pharmaceutical Healthcare Association.
Big Pharma
18 October 2018   The supplementary protection certificate manufacturing waiver “sends a worrying global signal that the EU is weakening its IP framework”, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Big Pharma
16 November 2018   Supplementary protection certificates are hugely important to MSD’s business, according to Elena Böhles, assistant counsel at the pharmaceutical company, based in Hertfordshire, UK.

More on this story

Big Pharma
9 August 2018   A proposed change to supplementary protection certificate rules in the EU could lead to the development of less innovative medicines, according to the Irish Pharmaceutical Healthcare Association.
Big Pharma
18 October 2018   The supplementary protection certificate manufacturing waiver “sends a worrying global signal that the EU is weakening its IP framework”, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Big Pharma
16 November 2018   Supplementary protection certificates are hugely important to MSD’s business, according to Elena Böhles, assistant counsel at the pharmaceutical company, based in Hertfordshire, UK.